

BACKGROUND

- The impact of stigma within mental health care has become much more widely understood.
- Research has shown that misperceptions and stigma of adults with Attention-Deficit/Hyperactivity Disorder (ADHD) are higher, compared to children.
- The impact of stigma on treatment seeking and maintenance among adult patients with ADHD is still highly under-investigated.

OBJECTIVES

- To identify perceptions and experiences of stigma among adults with ADHD actively engaged in treatment.
- To provide an anonymous space for adults with ADHD to express feelings and concerns regarding perceived and experienced stigma during the process of ADHD diagnosis, medication acquisition, and treatment.

METHODS

Study Design and Dissemination:

- 16-item Qualtrics survey administered via phone or email **Study Period:**
- November 2022 December 2022

Study Population:

Patients age 18 - 79 years old, with a diagnosis of ADHD and actively receiving care from a psychiatric provider at a Federally Qualified Health Center (FQHC) in St. Louis, Missouri

Sample Survey Questions:

- When seeking initial diagnosis and/or treatment for ADHD, how did you feel about doing so?
- 2. Approximately how long after your initial diagnosis of ADHD did you begin prescription stimulant medication(s)?
- How often are you required to visit or check-in with your prescriber to continue receiving your stimulant prescription(s)?
- 4. What barriers have you experienced related to obtaining your prescription stimulant medication for ADHD?
- 5. Have you felt hesitant to seek prescription stimulant treatment due to stigma (from pharmacy or prescriber office)?
- 6. Have you ever felt a need to change prescribers in order to feel less affected by the stigma regarding obtaining prescription stimulant medication(s)?
- 7. What feelings or comments would you like to express regarding what you think would be helpful for clinicians and/or pharmacies to know when helping patients with prescription stimulant treatment(s) in order for those patients to not feel stigmatized when receiving care?

- 3. Hipes C, Lucas J, Phelan JC, White RC. The stigma of mental illness in the labor market. Social Science Research. 2016; 56:16-25. 4. Centers for Disease Control and Prevention [Internet]. ADHD Treatment Recommendations: Diagnosis and Evaluation of ADHD. [updated 2022 Aug; cited 2022 Dec 22]. Atlanta (GA): Centers for Disease Control and Prevention. Available from:
- 5. Canu WH, Newman ML, Morrow TL, Pope DLW. Social appraisal of adult ADHD: stigma and influences of the beholder's Big Five personality traits. Journal of Attention Disorders. 2008; 11(6):700-710.
- 6. Ray L, Hinnant A. Media representation of mental disorders: A study of ADD and ADHD coverage in magazines from 1985 to 2008. Journal of Magazine & New Media *Research.* 2009; 11:1.

Patient-Experienced Stigma: Perceptions Regarding Obtaining Prescription Stimulant Attention-Deficit/Hyperactivity Disorder (ADHD) Medications

Erin Ball, Pharm.D. Candidate¹; Kelly N. Gable, PharmD, BCPP^{1,2}; Jaron Asher, MD² 1. Southern Illinois University Edwardsville, School of Pharmacy, 2. Family Care Health Centers, St. Louis, Missouri

Most Common Reported Barriers to Obtaining **Prescription Stimulant ADHD Medications**


Medication Not in Stock at the Pharmacy

Prescription "Too Soon" to Refill (Provider or Pharmacy Policy)

Prescription Requires Prior Authorization

0%

"I have felt judged or looked down upon for seeking to fill my prescription stimulant for ADHD treatment by:"




Specific Stigmatizing Perceptions/Experiences Creating Hesitancy to Seek Future Treatment

Anxiety/Worry Surrounding Required or Possibility of Required Urine Drug Screening


Fear of Being Perceived as "Doctor Shopping"

Being Labeled as Having A Substance Use Disorder

Perceptions On the Validity of Adult ADHD Diagnosis



RESULTS



- 89% were currently being prescribed a stimulant for ADHD.
- Most respondents (70%) indicated a 3-month required prescriber checkin to continue stimulant treatment.
- 32% reported feeling judgment by the pharmacist when filling their stimulant prescription.
- 8 reported stopping their prescription stimulant completely because of the experience of stigma during the course of their treatment.
- 41% reported feeling the need to change their prescribers in order to feel less affected by stigma.

- The highest rate of reported stigma was from pharmacist and pharmacy staff when acquiring prescription stimulant treatment.
- Commonly reported barriers to obtaining a prescription stimulant were drug availability, insurance issues, controlled substance refill policies, and pricing/insurance coverage.
- Compassion and understanding from their prescriber were mentioned by many participants as a necessary component of their treatment.
- Limitations

- Patients with an adult ADHD diagnosis experience stigma from multiple treatment points within the healthcare system.
- Stigma surrounding the process of ADHD diagnosis, medication acquisition, and treatment continues to be a major barrier toward seeking and maintaining stimulant treatment.
- Healthcare providers are encouraged to further explore the livedexperience of adults with ADHD to better understand and ultimately reduce stigmatizing behaviors.

SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE SCHOOL OF PHARMACY

RESULTS

• 27 participants completed the survey.

DISCUSSION

• Small patient sample size at one clinic location • Surveys conducted on site, which could lead to patients feeling untrusting of confidentiality of their responses

CONCLUSIONS

Scan the following QR code to review study participant feedback and comments on reducing stigma within adult ADHD care:



References:

er AB, Tucha L, Butzbach M, Weisbrod M, Aschenbrenner S, Tucha, O. Public perceptions of adult ADHD: Indications of stigma? Journal of Neural

uja M, Bink A, Buchholz B, Ellefson S, Fokuo K, Goldberg D, Kraus D, Leon A, Michaels P, Powell K, Schmidt A, Corrigan P. Challenging the stigma of mental illness among college students. *Journal of Adolescent Health.* 2016; 59:325-331.